SCHEMBL2551471

SCHEMBL2551471

COCCn1c(-c2cn(C)c(-c3ccc4scnc4c3)n2)nc2ccc(C)cc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.40
▸ RECQL P46063 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ BRD4 O60885 4/20 0.40
▸ HPGD P15428 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ CASR P41180 1/20 0.37
▸ PTGER4 P35408 7/20 0.37
▸ NPC1 O15118 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ AR P10275 1/20 0.35
▸ TP53 P04637 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ RIPK2 O43353 1/20 0.33
▸ AAK1 Q2M2I8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL14575705 0.92 PTGER4 (0.39) KDM4ERECQLHSD17B10BRD4HPGD
SCHEMBL2554816 0.84 KDM4E (0.37) KDM4ERECQLHSD17B10BRD4HPGD
SCHEMBL14616831 0.80 RIPK2 (0.47) KDM4ERECQLHSD17B10BRD4HPGD
SCHEMBL2554292 0.78 PTGER4 (0.38) KDM4ERECQLHSD17B10BRD4HPGD
SCHEMBL14575707 0.78 BRD4 (0.39) KDM4ERECQLHSD17B10BRD4HPGD
SCHEMBL14616786 0.78 PTGER4 (0.37) KDM4ERECQLHSD17B10BRD4HPGD
SCHEMBL2552122 0.76 PTGER4 (0.37) KDM4ERECQLHSD17B10BRD4HPGD
SCHEMBL2551037 0.75 PTGER4 (0.39) KDM4ERECQLHSD17B10BRD4HPGD
SCHEMBL2551655 0.75 RIPK2 (0.37) KDM4ERECQLHSD17B10BRD4HPGD
SCHEMBL14576227 0.74 KDM4E (0.39) KDM4ERECQLHSD17B10BRD4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US claimed
EP-2552208-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS Glaxo Group Limited (GB) 2013-02-06 — — EP disclosed
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed
WO-2011123609-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2011-10-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K3 KDM4E 764/4885RECQL 1347/4885HSD17B10 3817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback